Dr. Yilai Shu, a professor and chief physician at Eye & ENT Hospital of Fudan University, also serves as the Associate Dean of its Otolaryngology Institute. His clinical expertise lies in otology and neurotology. His research focuses on the prevention and treatment of deafness, particularly in gene therapy and clinical translational study. Dr. Shu has published numerous articles in The Lancet, BMJ, Science TM and Neuron. Notably, he has successfully developed a gene therapy candidate drug for the treatment of hearing loss caused by genetic defects and spearheaded the first clinical trial in this groundbreaking field.